Research Article

Factors Affecting Health-Related Quality of Life and Physical Activity after Liver Transplantation for Autoimmune and Nonautoimmune Liver Diseases: A Prospective, Single Centre Study

Katarzyna Kotarska,¹ Ewa Wunsch,²
Agnieszka Kempieńska-Podhorodecka,³ Joanna Raszeja-Wyszomirska,^{2,4}
Dimitrios P. Bogdanos,⁵ Maciej Wójcicki,⁴ and Piotr Milkiewicz^{2,4}

¹ Department of Physical Culture and Health Promotion, University of Szczecin, 70 067 Szczecin, Poland

² Liver Research Laboratories, Pomeranian Medical University, 70 111 Szczecin, Poland

³ Medical Biology Laboratory, Pomeranian Medical University, 70 111 Szczecin, Poland

⁴ Liver and Internal Medicine Unit, Department of General, Transplant and Liver Surgery of the Medical University of Warsaw 02 097 Warsaw, Poland

⁵ Institute of Liver Studies, Division of Liver Transplantation and Mucosal Biology, King's College London School of Medicine, Denmark Hill Campus, London SE5 9RS, UK

Correspondence should be addressed to Piotr Milkiewicz; milkiewp@sci.pum.edu.pl

Received 17 September 2013; Accepted 11 January 2014; Published 4 March 2014

Academic Editor: Eirini I. Rigopoulou

Copyright © 2014 Katarzyna Kotarska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background/Aim. With the improvement of the outcomes after liver transplantation (LTx), health-related quality of life (HRQoL) and physical activity are becoming significant outcome parameters. We prospectively assessed these parameters in patients with autoimmune and nonautoimmune liver disorders undergoing LTx. **Materials and Methods.** Patients ($n = 107$) were subdivided into 3 groups depending on the time after LTx: group-A ($n = 21$): 6–12 months; group-B ($n = 48$): 13–36 months; and group-C ($n = 38$): >37 months. SF-36 and IPAQ were applied in HRQoL and physical activity assessment. **Results.** Females had impaired HRQoL in most SF-36 domains. Younger patients showed higher scores at SF-36 *physical functioning* domain but IPAQ was not influenced by age. Group-B had higher *general health* and *physical component summary* than group-A ($P = 0.037$, $P = 0.04$, resp.) and total IPAQ than group-C ($P = 0.047$). The *sitting time* domain was longer in group-A than in group-B and group-C ($P = 0.0157$; $P = 0.042$, resp.). Employed patients had better HRQoL and higher physical activity than those not working. SF-36 and IPAQ were unrelated to the autoimmune etiology of liver disease. **Conclusions.** These findings show that female and unemployed patients have worse HRQoL, while gender and age at LTx time do not affect IPAQ's physical activity. The autoimmune etiology of liver disease does not influence HRQoL and physical activity after LTx.

1. Introduction

The final outcome of autoimmunity and the extent by which it progresses to clinically overt disease have a direct or indirect impact and/or are influenced by parameters associated with health-related quality of life (HRQoL). HRQoL

is a multidimensional concept that includes subjective evaluations of domains related to physical, mental, emotional, and social functioning in a context of a disease or disability and their treatment [1]. An evaluation of HRQoL denotes an effort to define how variables within the dimension of health relate to specific measurements that have been found to be of

importance to subjects [2]. With the improvement of medical treatments followed by prolongation of survival, HRQoL has emerged as an important clinical issue. Several studies have demonstrated that the HRQoL in patients with chronic liver conditions is significantly impaired [3–6]. This refers in particular to those subjects with liver cirrhosis complicated with hepatic encephalopathy, ascites, or pruritus [7–10]. However, several HRQoL parameters are also impaired in noncirrhotic patients with chronic liver diseases, such as those suffering from primary biliary cirrhosis (PBC) [11–13]. We have recently shown that certain genes related with immune dysregulation are tightly involved in the impairment of HRQoL in PBC, long before the need for LTx [14]. Quality of life improves considerably after liver transplantation (LTx); nevertheless, transplant recipients show lower HRQoL scores than the general population [15]. Regular physical activity has been demonstrated to be of significance in long-term recovery process after LTx and to positively affect quality of life [16]; however, many liver transplant recipients are sedentary [17, 18]. A low physical activity contributes to the development of posttransplant metabolic abnormalities and cardiovascular complications, which are the third leading cause of long-term mortality after LTx [17, 19]. To date, there are limited data on factors related to low physical activity and impaired HRQoL in liver transplant recipients. We ourselves previously noted that specific factors of HRQoL are significantly impaired in patients with autoimmune liver diseases, and in particular in patients with primary biliary cirrhosis (PBC), an autoimmune cholestatic disease [11]. Patients who require LTx due to autoimmune liver disorders also include those with primary sclerosing cholangitis (PSC) and—nowadays to a lesser extent—patients affected with autoimmune hepatitis (AIH). Taking into account that most patients requiring LTx are largely subdivided to those with autoimmune liver diseases, viral hepatitis, or alcoholic liver disease, we have considered that it would be of interest to investigate the factors that affect HRQoL in transplanted patients, paying special attention to those with autoimmune liver diseases. This could give us insight as to whether autoimmunity may have a profound effect in HRQoL and physical activity factors that could be distinguished from those seen in patients with nonautoimmune liver conditions. Our consecutive cohort of LTx patients offered us two unique opportunities: first, to study HRQoL in undivided LTx recipients without paying special attention to the underlying liver disease. This has given us the opportunity to assess prospectively several factors that affect HRQoL and physical functions in patients who underwent LTx in our centre. We also stratified our patients to those with autoimmune and nonautoimmune liver diseases and compared their characteristics.

2. Materials and Methods

2.1. Patients. One hundred and seven (62 males/45 females) consecutive liver transplant recipients reviewed in our Out-Patient Clinic were included in the study between June 2011 and October 2012. All patients were enrolled at least 6 months after the surgical procedure. Patients were divided into 3

TABLE 1: Demographic and clinical data on analyzed patients.

Total number of patients	<i>n</i> = 107
Age at transplantation [years, mean $\pm$ SD (range)]	46.7 $\pm$ 11.6 (17–63)
Age at survey [years, mean $\pm$ SD (range)]	49.9 $\pm$ 11.4 (21–67)
Gender [male/female]	62 (57.9%)/45 (42.1%)
BMI [kg/m ² , mean $\pm$ SD (range)]	27.0 $\pm$ 5.0 (18.0–43.0)
Period after transplantation	
Group-A (6–12 months)	21 (19.6%)
Group-B (13–36 months)	48 (44.9%)
Group-C (>36 months)	38 (35.5%)
Employment (yes/no)	40 (37.4%)/67 (62.6%)
Original diagnosis	
Alcohol liver disease	24 (22.4%)
Viral hepatitis	15 (14.0%)
Autoimmune hepatitis	10 (9.4%)
Autoimmune cholestatic (PBC, PSC)	23 (21.5%)
Other*	35 (32.7%)

Group-A: 6 months to 12 months after liver transplantation; group-B: from 12 months to 36 months after liver transplantation; group-C: over 36 months after liver transplantation; *other reasons for LTx included cryptogenic cirrhosis (*n* = 8); Fulminant Wilson's (*n* = 5), chronic Wilson's (*n* = 2); non-A, non-B hepatitis (*n* = 7); amanita poisoning (*n* = 7); Budd-Chiari syndrome (*n* = 4); secondary biliary cirrhosis (*n* = 1) and acute fatty liver of pregnancy (*n* = 1). BMI: body mass index; PBC: primary biliary cirrhosis; PSC: primary sclerosing cholangitis.

groups, depending on the period after LTx: (group-A, *n* = 21): 6–12 months after LTx; (group-B, *n* = 48): 13–36 months after LTx; and (group-C, *n* = 38): more than 37 months after LTx. Indications for LTx included the following etiologies: alcoholic (*n* = 24), chronic autoimmune cholestatic liver diseases (PBC and PSC, total *n* = 23), AIH (*n* = 10), viral hepatitis (*n* = 15, 11 chronic hepatitis C, 4 chronic hepatitis B), and various other causes of liver disease (*n* = 35).

The demographic data of the participating patients are summarized in Table 1.

The patients under investigation were clinically stable and did not suffer from LTx-related complications and severe comorbidities, which could influence their HRQoL or physical activity, such as malignancy, decompensated diabetes mellitus, renal insufficiency requiring dialysis, heart failure $\geq$ NYHA II, physical disability, orthopedic disorders, rheumatoid arthritis, or pulmonary disease. The mean body mass index (BMI) of included subjects was 27.0 $\pm$ 5.0 kg/m². Thirty-eight (35.5%) patients were overweight (BMI between 25 and 30 kg/m²) and 23 (21.5%) were obese (BMI $\geq$ 30 kg/m²).

Forty patients (37.4%) were employed at the time of the survey. Among 67 subjects, who were not working, 21 (31.3%) were retired pensioners and 46 (68.7%) were disability pensioners. Patients with an active profession were younger than patients who did not work (retired or disability pensioners) (45.7 $\pm$ 12.8 versus 52.5 $\pm$ 9.8 years, *P* = 0.003).

The two groups, however, did not differ in relation to gender and the time duration after LTx (data not shown).

2.2. Assessment of Health-Related Quality of Life. HRQoL was assessed with the Medical Outcomes Study Short Form (SF-36). The SF-36 is the most widely used and extensively validated generic questionnaire for the assessment of HRQoL in various clinical settings and different populations [20]. It consists of 36 items, grouped in 8 domains, in the area of physical health (domains: *physical functioning*, *role limitations due to physical problems*, *bodily pain*, and *general health*) and mental health (domains: *vitality*, *social functioning*, *role limitations due to emotional problems*, and *mental health*). Each domain is scored between 0 to 100 points, with higher scores indicating better HRQoL. Two summary scores, *physical component* and *mental component*, are obtained as a mean value calculated based on the corresponding domains. This study was carried out under a licensed approval certificate (CT132326/OP012559) for the use of the SF-36 questionnaire.

2.3. Assessment of Physical Activity. For the assessment of physical activity the Polish long version of International Physical Activity Questionnaire (IPAQ) was used [21]. IPAQ is an instrument for monitoring levels of physical activity of an adult population between 15 and 69 years and was developed for surveillance activities and to guide policy development related to health-enhancing physical activity across various life domains. The long version of the IPAQ comprises 27 items and investigates 4 physical activity domains (work, leisure, chores, and transport), as well as time spent sitting as a proxy for sedentary behavior [22]. Physical activity is reported as a continuous score, by domain and by intensity of physical activity (moderate or vigorous), or for *walking*. Physical activity energy expenditure is calculated according to the following formula (in MET-min-week-1): number of days spent doing the activity $\times$ average duration of the activity per day $\times$ energy cost of the activity. The energy cost of an activity is expressed in MET (metabolic equivalent task). A MET is the ratio of the energy expenditure during a given activity divided by the resting energy expenditure [23].

The following MET values were drawn from the scoring protocol: 3.3 for *walking*, 4 for moderate intensity physical activity, 8.0 for vigorous physical activity, 6.0 for cycling, 5.5 for vigorous physical activity in the garden or yard, and 3.0 for domestic activities [24].

2.4. Ethics. Written informed consent was obtained from each patient included in the study. The study protocol was approved by the appropriate Ethics Committee of Pomeranian Medical University and conformed to the ethical guidelines of the 1975 Declaration of Helsinki (6th revision, 2008).

2.5. Statistics. Data are shown as means and standard deviations. The SF-36 and IPAQ scores were correlated with various clinical factors of potential significance. Data were analyzed using Stat-View-5 Software (SAS Institute, Cary, NC, USA) using Fisher's exact and ANOVA analysis. Categorical data were compared using Levene's test for equality of

variances and both pooled-variances and separate-variances *t*-tests for equality of means. Correlations were tested with Pearson Correlation test. *P* value < 0.05 was considered statistically significant.

3. Results

3.1. Quality of Life. Age was comparable between female and male patients at the time of the survey (50.7 ± 11.9 versus 49.4 ± 11.1 years, respectively; $P = 0.56$); still, all but two (*role limitations due to physical problems* and *general health*) domains of SF-36 HRQoL were worse in females compared to males (Table 2(a)). The most profound impairment was noted in the domains of *bodily pain* ($P = 0.0004$) and *role limitations due to physical problems* ($P = 0.0001$).

Younger patients scored higher at *physical functioning* domain ($r = -0.295$, $P = 0.002$). That domain subsequently showed a significantly negative correlation with the age at LTx ($r = -0.297$, $P = 0.002$). Regarding the time period after LTx, a significant improvement in group-B compared to group-A was seen in terms of *general health* ($P = 0.037$) and *physical component summary* ($P = 0.04$) domains (Table 2(b)). The underlying cause of the disease/indication for LTx had no effect on HRQoL (data not shown). Active workers had significantly better HRQoL in most domains of physical aspect of well-being, including *physical functioning*, *role limitations due to physical problems*, *bodily pain*, *physical component summary*, and *role limitations due to emotional problems* compared to pensioners due to retirement or disability (Table 3(a)). BMI correlated negatively with *physical functioning* domain ($r = -0.221$, $P = 0.022$) and *physical component summary* ($r = -0.207$, $P = 0.032$). Obese patients ($\text{BMI} \geq 30 \text{ kg/m}^2$) showed significantly reduced HRQoL in domains: *physical functioning*, *general health*, and *physical component summary* (Table 3(b)).

3.2. Physical Activity. Amongst analyzed patients, distribution of activity was as follows: *total activity*: 4497.1 ± 3375.7 MET-min/week (range: 1056.0–22740.0 MET-min/week), *walking*: 1286.4 ± 910.8 MET-min/week (range: 0.0–4158.0 MET-min/week), *moderate activity*: 2402.9 ± 1368.7 MET-min/week (range: 180.0–6930.0 MET-min/week), *vigorous activity*: 807.9 ± 3151.7 MET-min/week (range: 0.0–21480.0 MET-min/week), and *sitting time* 633.5 ± 181.3 min-week (range: 300.0–1080.0 min-week). Eighty-four patients (44 males) did not undertake any *vigorous activity*. No difference in physical activity between males and females both in terms of total and specific domains of IPAQ was seen, except of *vigorous activity* (Table 4(a)). No correlation was observed with IPAQ and age at survey or age at surgery and the underlying cause of the disease/indication for LTx (data not shown). Group-B was more active with regard to total IPAQ (5333.4 ± 4553.7 MET-min/week) versus group-C (3882.6 ± 1538.9 MET-min/week, $P = 0.047$). Group-B tended to be more active than group-A (3697.6 ± 2053.3 MET-min/week, $P = 0.06$, Table 4(b)). As expected, *sitting time* domain was significantly longer in group-A (720.0 ± 171.8 min-week) than in group-B

TABLE 2: (a) Comparison of SF-36 domains in male and female patients. (b) Quality of life parameters in relation to the time after liver transplantation.

(a)						
SF 36	Males (<i>n</i> = 62)		Females (<i>n</i> = 45)		<i>P</i> value	
PF	78.5 ± 22.2		63.9 ± 22.5		0.001	
RP	67.6 ± 26.2		58.6 ± 20.0		0.05	
BP	79.4 ± 25.4		60.5 ± 28.2		0.0004	
GH	61.9 ± 20.2		56.3 ± 18.4		0.14	
VT	64.9 ± 16.1		55.8 ± 18.4		0.0077	
SF	79.4 ± 20.4		66.1 ± 79.4		0.0023	
RE	81.5 ± 20.0		65.2 ± 21.5		0.0001	
MH	71.1 ± 15.4		62.1 ± 17.4		0.0057	
PCS	48.2 ± 9.1		43.7 ± 7.6		0.0073	
MCS	48.9 ± 8.2		43.1 ± 9.9		0.0015	

(b)						
SF 36	A (<i>n</i> = 21)	B (<i>n</i> = 48)	C (<i>n</i> = 38)	<i>P</i> (A versus B)	<i>P</i> (A versus C)	<i>P</i> (B versus C)
PF	66.7 ± 25.1	71.8 ± 25.7	76.2 ± 18.7	0.405	0.136	0.386
RP	55.4 ± 24.9	65.6 ± 23.0	66.3 ± 24.8	0.105	0.096	0.899
BP	62.2 ± 25.2	74.2 ± 27.7	73.0 ± 29.6	0.105	0.159	0.845
GH	52.7 ± 18.5	63.4 ± 18.5	58.4 ± 20.7	0.037	0.280	0.239
VT	61.0 ± 15.3	60.6 ± 17.9	61.8 ± 18.8	0.920	0.864	0.737
SF	75.6 ± 21.1	77.1 ± 23.7	68.8 ± 21.7	0.801	0.266	0.091
RE	68.7 ± 25.4	75.2 ± 22.2	77.2 ± 19.8	0.261	0.157	0.674
MH	67.9 ± 11.7	67.0 ± 17.3	67.5 ± 18.8	0.839	0.938	0.882
PCS	42.5 ± 8.8	47.3 ± 8.4	47.2 ± 8.9	0.04	0.051	0.967
MCS	47.0 ± 8.6	46.6 ± 9.6	46.9 ± 9.8	0.8819	0.6964	0.7569

All values are shown as mean ± SD.

Group-A: 6 months to 12 months after liver transplantation; group-B: from 12 months to 36 months after liver transplantation; group-C: over 36 months after liver transplantation.

PF: physical functioning; RP: role limitations due to physical problems; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role limitations due to emotional problems; MH: mental health; PF: physical functioning; PCS: physical component score; MCS: mental component score.

(605.8 ± 174.5 min-week, $P = 0.0157$) and group-C (620.5 ± 184.7 min-week, $P = 0.042$, Table 4(b)). Participants who commenced an employment after LTx showed significantly higher physical activity in total IPAQ and in *vigorous activity* domains in comparison to patients out of work ($P = 0.005$ and $P = 0.0014$, resp., Table 5(a)). There was a trend towards a negative correlation between lower *total activity* and BMI ($r = -0.174$, $P = 0.07$). In comparison to patients with ideal weight, overweight patients were less active in relation to *total activity* and *vigorous activity* ($P = 0.0082$ and $P = 0.047$, resp.), and obese subjects showed reduced *total activity* ($P = 0.027$, Table 5(b)).

3.3. Relationship between Physical Activity and Quality of Life after Liver Transplantation. From all domains of SF-36 questionnaire, only *social functioning* domain correlated negatively with *sitting time* domain of IPAQ ($r = -0.203$, $P = 0.036$).

3.4. HRQoL and Physical Function Test Parameters in Patients with Autoimmune and Nonautoimmune Liver Diseases. As we mentioned, the indication for LTx did not affect HRQoL

and physical activity. We then compared patients with underlying autoimmune liver diseases (AIH, PBC, and PSC) with those without autoimmune liver diseases, in relation to specific SF-36 HRQoL and IPAQ physical activity performance. When LTx patients were stratified according to the presence of autoimmune liver disease or not as the cause of the underlying disease, we did not observe any differences in terms of well-being or physical activity (Table 6).

4. Discussion

Several studies have shown that HRQoL improves considerably after LTx. Nevertheless, transplant recipients demonstrate lower HRQoL scores and remain less physically active than the general population [25–28]. In this study, we prospectively assessed the factors that can influence daily living and physical behaviors in 107 patients, who underwent LTx in our centre.

In subgroup analysis, we found that the cause of transplantation did not influence physical activities and perception of daily life (Table 5). This is an important topic because a substantial group of patients with liver diseases (in our cohort

TABLE 3: (a) Professional work status (employment versus pension) and quality of life features in liver transplant recipients. (b) Nutritional status (body mass index, BMI) and quality of life in analyzed patients.

(a)						
SF 36	Employed (<i>n</i> = 40)		Pensioners (<i>n</i> = 67)		<i>P</i> value	
PF	81.3 ± 19.6		67.0 ± 23.9		0.002	
RP	72.3 ± 23.3		58.8 ± 23.4		0.004	
BP	81.1 ± 24.4		65.7 ± 28.7		0.005	
GH	61.6 ± 23.4		58.3 ± 16.9		0.407	
VT	63.5 ± 17.1		59.7 ± 17.8		0.298	
SF	77.8 ± 22.4		71.5 ± 22.6		0.161	
RE	83.5 ± 18.2		69.3 ± 22.6		0.001	
MH	71.0 ± 17.3		65.2 ± 16.2		0.083	
PCS	49.4 ± 8.6		44.5 ± 8.4		0.005	
MCS	48.3 ± 8.6		45.4 ± 9.7		0.113	

(b)						
SF 36	1 (<i>n</i> = 46)	2 (<i>n</i> = 38)	3 (<i>n</i> = 23)	<i>P</i> (1 versus 2)	<i>P</i> (1 versus 3)	<i>P</i> (2 versus 3)
PF	74.7 ± 23.5	77.4 ± 19.8	59.3 ± 24.7	0.59	0.0089	0.0031
RP	65.1 ± 24.5	66.8 ± 24.1	56.5 ± 22.96	0.75	0.17	0.11
BP	71.9 ± 27.9	74.3 ± 29.03	65.6 ± 26.9	0.69	0.38	0.25
GH	60.4 ± 19.7	63.5 ± 21.1	51.3 ± 14.1	0.46	0.07	0.017
VT	60.9 ± 20.2	63.5 ± 15.5	57.6 ± 15.2	0.49	0.47	0.21
SF	71.2 ± 24.3	75.98 ± 21.8	75.5 ± 20.8	0.34	0.45	0.94
RE	73.4 ± 24.6	76.1 ± 19.8	74.6 ± 21.1	0.58	0.82	0.80
MH	66.2 ± 16.7	70.2 ± 18.1	64.8 ± 14.7	0.28	0.74	0.22
PCS	47.3 ± 8.1	48.01 ± 9.3	41.5 ± 7.8	0.71	0.0081	0.0043
MCS	45.2 ± 10.6	47.3 ± 8.6	47.5 ± 8.04	0.32	0.36	0.95

All values are shown as mean ± SD.

Group 1: normal BMI (18–25 kg/m²), group 2: overweight (BMI 25–30 kg/m²), group 3: obese (BMI ≥30 kg/m²).

PF: physical functioning; RP: role limitations due to physical problems; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role limitations due to emotional problems; MH: mental health; PCS: physical component score; MCS: mental component score.

TABLE 4: (a) Physical activity in relation to gender and (b) the time after liver transplantation.

(a)			
IPAQ	Males (<i>n</i> = 62)	Females (<i>n</i> = 45)	<i>P</i>
Total (MET-min/week)	4912.8 ± 4027.8	3924.4 ± 2093.3	0.136
Walking (MET-min/week)	1222.9 ± 794.8	1373.9 ± 1053.3	0.399
Moderate (MET-min/week)	2342.2 ± 1322.9	2486.5 ± 1440.2	0.593
Vigorous (MET-min/week)	1347.7 ± 4064.9	64.0 ± 212.1	0.03
Sitting time (min-week)	621.9 ± 176.1	649.3 ± 189.0	0.443

(b)						
IPAQ	A (<i>n</i> = 21)	B (<i>n</i> = 48)	C (<i>n</i> = 38)	<i>P</i> (A versus B)	<i>P</i> (A versus C)	<i>P</i> (B versus C)
Total (MET-min/week)	3697.6 ± 2053.3	5333.4 ± 4553.7	3882.6 ± 1538.9	0.06	0.83	0.047
Walking (MET-min/week)	1216.2 ± 890.5	1350.6 ± 1027.7	1244 ± 772.4	0.577	0.912	0.594
Moderate (MET-min/week)	2119.5 ± 1158.7	2548.7 ± 1601.4	2375.4 ± 1144.3	0.235	0.494	0.562
Vigorous (MET-min/week)	361.9 ± 1568.0	1464.2 ± 4506.9	263.2 ± 632.6	0.193	0.91	0.08
Sitting time (min-week)	720.0 ± 171.8	605.8 ± 174.5	620.5 ± 184.7	0.016	0.042	0.7

All values are shown as mean ± SD.

Group-A: 6 months to 12 months after liver transplantation; group-B: from 12 months to 36 months after liver transplantation; group-C: over 36 months after liver transplantation.

TABLE 5: (a) Professional work status (employment versus pension) and physical activity in liver transplant recipients. (b) Nutritional status (body mass index, BMI) and physical activity in analyzed patients.

(a)						
IPAQ	Employed (<i>n</i> = 40)		Pensioners (<i>n</i> = 67)		<i>P</i>	
Total (MET-min/week)	5668.2 ± 4787.0		3797.9 ± 1852.8		0.005	
Walking (MET-min/week)	1287.5 ± 870.9		1287.5 ± 985.5		0.98	
Moderate (MET-min/week)	2340.7 ± 1451.7		2440.0 ± 1326.5		0.71	
Vigorous (MET-min/week)	2043.0 ± 4934.6		70.5 ± 296.9		0.0014	
Sitting time (min-week)	632.5 ± 173.2		634.0 ± 187.2		0.96	
(b)						
IPAQ	1 (<i>n</i> = 46)	2 (<i>n</i> = 38)	3 (<i>n</i> = 23)	<i>P</i> (1 versus 2)	<i>P</i> (1 versus 3)	<i>P</i> (2 versus 3)
Total (MET-min/week)	5585.3 ± 4599.4	3651.9 ± 1635.4	3717.3 ± 1670.0	0.0082	0.027	0.93
Walking (MET-min/week)	1361.2 ± 1179.2	1283.1 ± 686.8	1142.1 ± 571.1	0.70	0.35	0.56
Moderate (MET-min/week)	2600.5 ± 1294.0	2109.8 ± 1337.5	2491.7 ± 1534.2	0.10	0.75	0.29
Vigorous (MET-min/week)	1623.5 ± 4674.7	258.9 ± 567.3	83.5 ± 400.3	0.047	0.054	0.83
Sitting time (min-week)	663.5 ± 182.9	593.7 ± 183.9	639.1 ± 168.4	0.08	0.59	0.34

All values are shown as mean $\pm$ SD.

Group 1: normal BMI (18–25 kg/m²); group 2: overweight (BMI 25–30 kg/m²); group 3: obese (BMI ≥ 30 kg/m²).

TABLE 6: Quality of life and physical activity after liver transplantation in patients with autoimmune versus nonautoimmune etiology of liver disease.

	Autoimmune ($n = 33$)	Nonautoimmune ($n = 74$)	P value
SF 36			
PF	69.1 $\pm$ 23.4	73.8 $\pm$ 23.3	0.339
RP	62.1 $\pm$ 23.3	64.6 $\pm$ 24.6	0.624
BP	66.5 $\pm$ 27.7	73.6 $\pm$ 28.1	0.232
GH	56.8 $\pm$ 21.4	60.8 $\pm$ 18.7	0.335
VT	60.4 $\pm$ 16.9	61.4 $\pm$ 18.0	0.790
SF	72.0 $\pm$ 19.0	74.7 $\pm$ 24.1	0.572
RE	72.2 $\pm$ 21.8	75.7 $\pm$ 22.2	0.457
MH	66.2 $\pm$ 17.8	67.8 $\pm$ 16.4	0.650
PCS	44.9 $\pm$ 8.9	47.0 $\pm$ 8.7	0.256
MCS	46.0 $\pm$ 8.6	47.7 $\pm$ 9.8	0.732
IPAQ			
Total (MET-min/week)	4464.4 $\pm$ 3370.3	4511.7 $\pm$ 3401.0	0.947
Walking (MET-min/week)	1483.0 $\pm$ 901.6	1198.7 $\pm$ 907.2	0.137
Moderate (MET-min/week)	2077.1 $\pm$ 1043.8	2548.2 $\pm$ 1474.1	0.100
Vigorous (MET-min/week)	904.2 $\pm$ 3147.2	764.9 $\pm$ 3174.2	0.834
Sitting time (min/week)	620.0 $\pm$ 182.9	639.5 $\pm$ 181.5	0.610

All values are shown as mean $\pm$ SD.

PF: physical functioning; RP: role limitations due to physical problems; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role limitations due to emotional problems; MH: mental health; PCS: physical component score; MCS: mental component score.

31%) stems from an underlying autoimmune disease (PBC, PSC, or AIH), and this could help us delineate the extent by which the autoimmune nature of the original disease may impact the overall performance scores. Our analysis suggests that the mechanisms leading to end-stage liver failure and LTx are irrelevant to the HRQoL and physical activity of patients who have undergone LTx. On the other hand, older age was a factor significantly impairing HRQoL, but this feature is also seen in the general population and by no means can be seen as a major contributing factor [29]. As

was expected, we observed that patients in their first 6–12 months after LTx demonstrate more sedentary habits; such features are most likely related to recovery and fear of pain due to physical efforts. In contrast, patients assessed in their second and third year after LTx showed increasing physical activity and improved physical aspects of well-being such as *general health* and *physical component summary* of SF-36. An apparent explanation for this finding is that full recovery enables these patients to perform better in terms of more demanding physical effort and active lifestyle needs

[17]. Gross et al. have reported similar findings and noted that limitations in several activities due to patients' role and physical health problems virtually cease a year after LTx [27]. Somewhat surprisingly, this trend was not observed in LTx patients studied 36 months or after the procedure. In these patients, there was no further improvement in the quality of their life, while physical activity was again significantly decreased. The long-term impairment of physical functions in liver transplant recipients has also been noted by other investigators [15]. While the overall perception of health improves after LTx, a significant proportion of patients suffer from chronic complaints such as chronic pain or fatigue, which restricts their physical activity [30–33]. However, in our group of patients we did not observe such unwanted symptoms (low scores at *bodily pain* SF-36 domain).

Data assessing the impact of physical activity on nutritional status in liver transplant recipients are limited. Kallwitz et al. showed that the metabolic syndrome is common after LTx with higher prevalence in patients over 1 year after LTx, and is inversely correlated with exercise intensity [18]. Published data showed an association of higher activity levels with lower rates of hypertension and a lower BMI [16]. We found an obese or overweight habitus strongly associated with reduced physical activity and impaired physical components of HRQoL, but the interpretation of our findings is not an easy task as we do not know whether physical inactivity (and lower HRQoL scores) precedes or follows that of increased BMI.

Patients doing their professional work had significantly better scores of SF-36, mainly related to physical aspects of well-being (i.e., *physical functioning*, *role limitations due to physical problems*, *bodily pain*, *physical component summary*, and *role limitations due to emotional problems*) and were significantly more physically active than those out of work (pensioners). These observations are in agreement with previous studies, in which persons that had an active work life had significantly better HRQoL compared to those out of work [15, 34–36]. Liver transplant recipients more frequently experience fatigue and demonstrate lower SF36 *physical functioning* scores than those engaged in any educational or working activity [37]. This has been attributed to the fact that professional work provides external stimuli and allows the return to normal lifestyle and social integration [38]. Also, fulfillment of professional tasks and work satisfaction enhances the sense of independence. Thus, patients who remain out of work may potentially be less motivated and have more impaired physical activity than those with an active work life.

Perhaps the most striking finding of this analysis is a significantly worse HRQoL in female patients in the majority of SF-36 domains. This new finding contrasts published data reporting comparable HRQoL scores between males and females. In agreement with our data, Cowling et al. found better quality of life in male subjects using their own HRQoL questionnaire, specifically designated for LTx patients [39]. In other disciplines, HRQoL is worse in female patients with coronary artery disease than in men [40], while women with early rheumatoid arthritis perform better in terms of HRQoL than their male counterparts [41]. Gender-related

differences on quality of life parameters are complex and deserve thorough investigation.

We are aware of the constraints of the present study. For example, recurrence of the original disease including viral hepatitis, PBC, or PSC may affect HRQoL parameters. Amongst the 11 chronic hepatitis C patients, 5 had recurrent disease which required initiation of antiviral treatment including two who achieved sustained virological response but the treatment finished 4 years and 1 year before the inclusion in the study, respectively. Thus, it is rather unlikely that recurrence is a precipitating factor which could affect the current analyses, though such an effect cannot be excluded. Another limitation is that the study did not include data on healthy subjects and is cross-sectional in nature and not longitudinal study. Nevertheless, it provides important information regarding the impact of environment in the form of HRQoL and physical activity features after LTx. Our findings suggest that the indication for transplantation (autoimmune or nonautoimmune) does not influence the quality of life but emphasizes the role of employment in complete recovery and return to normal life. We underline differences amongst gender in perception of daily life and a profound impairment of SF-36 scores in females.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

- [1] The Whoqol Group, "World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties," *Social Science and Medicine*, vol. 46, no. 12, pp. 1569–1585, 1998.
- [2] J. E. Ware Jr., "The status of health assessment 1994," *Annual Review of Public Health*, vol. 16, pp. 327–354, 1995.
- [3] J. Córdoba, M. Flavià, C. Jacas et al., "Quality of life and cognitive function in hepatitis C at different stages of liver disease," *Journal of Hepatology*, vol. 39, no. 2, pp. 231–238, 2003.
- [4] W. Häuser, G. Holtmann, and D. Grandt, "Determinants of health-related quality of life in patients with chronic liver diseases," *Clinical Gastroenterology and Hepatology*, vol. 2, no. 2, pp. 157–163, 2004.
- [5] Z. M. Younossi, M. L. Kiwi, N. Boparai, L. L. Price, and G. Guyatt, "Cholestatic liver diseases and health-related quality of life," *American Journal of Gastroenterology*, vol. 95, no. 2, pp. 497–502, 2000.
- [6] Z. M. Younossi, N. Boparai, L. L. Price, M. L. Kiwi, M. McCormick, and G. Guyatt, "Health-related quality of life in chronic liver disease: the impact of type and severity of disease," *American Journal of Gastroenterology*, vol. 96, no. 7, pp. 2199–2205, 2001.
- [7] M. R. Arguedas, T. G. DeLawrence, and B. M. McGuire, "Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis," *Digestive Diseases and Sciences*, vol. 48, no. 8, pp. 1622–1626, 2003.
- [8] I. Les, E. Doval, M. Flavià et al., "Quality of life in cirrhosis is related to potentially treatable factors," *European Journal of*

- Gastroenterology and Hepatology*, vol. 22, no. 2, pp. 221–227, 2010.
- [9] G. Marchesini, G. Bianchi, P. Amodio et al., “Factors associated with poor health-related quality of life of patients with cirrhosis,” *Gastroenterology*, vol. 120, no. 1, pp. 170–178, 2001.
 - [10] E. Wunsch, G. Naprawa, D. Koziarska, M. Milkiewicz, P. Nowacki, and P. Milkiewicz, “Serum natremia affects health-related quality of life in patients with liver cirrhosis: a prospective, single centre study,” *Annals of Hepatology*, vol. 12, no. 3, pp. 448–455, 2013.
 - [11] G. F. Mells, G. Pells, J. L. Newton et al., “Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study,” *Hepatology*, vol. 58, no. 1, pp. 273–283, 2013.
 - [12] C. Selmi, M. E. Gershwin, K. D. Lindor et al., “Quality of life and everyday activities in patients with primary biliary cirrhosis,” *Hepatology*, vol. 46, no. 6, pp. 1836–1843, 2007.
 - [13] P.-M. Huet, J. Deslauriers, A. Tran, C. Faucher, and J. Charbonneau, “Impact of fatigue on the quality of life of patients with primary biliary cirrhosis,” *American Journal of Gastroenterology*, vol. 95, no. 3, pp. 760–767, 2000.
 - [14] J. Raszeja-Wyszomirska, E. Wunsch, A. Kempinska-Podhorodecka et al., “TRAF1-C5 affects quality of life in patients with primary biliary cirrhosis,” *Clinical and Developmental Immunology*, vol. 2013, Article ID 510547, 7 pages, 2013.
 - [15] D. Masala, A. Mannocci, B. Unim, Quality of life a et al., “nd physical activity in liver transplantation patients: results of a case-control study in Italy,” *Transplantation Proceedings*, vol. 44, no. 5, pp. 1346–1350, 2012.
 - [16] P. Painter, J. Krasnoff, S. M. Paul, and N. L. Ascher, “Physical activity and health-related quality of life in liver transplant recipients,” *Liver Transplantation*, vol. 7, no. 3, pp. 213–219, 2001.
 - [17] N. Beyer, M. Aadahl, B. Strange et al., “Improved physical performance after orthotopic liver transplantation,” *Liver Transplantation and Surgery*, vol. 5, no. 4, pp. 301–309, 1999.
 - [18] E. R. Kallwitz, V. Loy, P. Mettu, R. N. Von, J. Berkes, and S. J. Cotler, “Physical activity and metabolic syndrome in liver transplant recipients,” *Liver Transplantation*, vol. 19, no. 10, pp. 1125–1131, 2013.
 - [19] K. D. S. Watt, R. A. Pedersen, W. K. Kremers, J. K. Heimbach, and M. R. Charlton, “Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study,” *American Journal of Transplantation*, vol. 10, no. 6, pp. 1420–1427, 2010.
 - [20] J. E. Ware Jr. and C. D. Sherbourne, “The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection,” *Medical Care*, vol. 30, no. 6, pp. 473–483, 1992.
 - [21] E. Biernat, R. Stupnicki, and A. Gajewski, “Międzynarodowy kwestionariusz aktywności fizycznej (IPAQ)—wersja polska,” *Wychowanie Fizyczne I Sport*, vol. 51, no. 1, pp. 47–54, 2007.
 - [22] J. Bergier, L. Kapka-Skrzypczak, P. Biliński, P. Paprzycki, and A. Wojtyła, “Physical activity of Polish adolescents and young adults according to IPAQ: a population based study,” *Annals of Agricultural and Environmental Medicine*, vol. 19, no. 1, pp. 109–115, 2012.
 - [23] Y. Kim, I. Park, and M. Kang, “Convergent validity of the international physical activity questionnaire (IPAQ): meta-analysis,” *Public Health Nutrition*, vol. 16, no. 3, pp. 440–452, 2013.
 - [24] Guidelines for data processing and analysis of the IPAQ, 2013, <http://www.ipaq.ki.se/>.
 - [25] S. H. Belle, M. K. Porayko, J. H. Hoofnagle, J. R. Lake, and R. K. Zetterman, “Changes in quality of life after liver transplantation among adults,” *Liver Transplantation and Surgery*, vol. 3, no. 2, pp. 93–104, 1997.
 - [26] M. De Bona, P. Ponton, M. Ermani et al., “The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation,” *Journal of Hepatology*, vol. 33, no. 4, pp. 609–615, 2000.
 - [27] C. R. Gross, M. Malinchoc, W. Ray Kim et al., “Quality of life before and after liver transplantation for cholestatic liver disease,” *Hepatology*, vol. 29, no. 2, pp. 356–364, 1999.
 - [28] J. Ratcliffe, L. Longworth, T. Young, S. Bryan, A. Burroughs, and M. Buxton, “Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study,” *Liver Transplantation*, vol. 8, no. 3, pp. 263–270, 2002.
 - [29] J. P. Browne, C. A. O’Boyle, H. M. McGee et al., “Individual quality of life in the healthy elderly,” *Quality of Life Research*, vol. 3, no. 4, pp. 235–244, 1994.
 - [30] R. van den Berg-Emons, B. van Ginneken, M. Wijffels et al., “Fatigue is a major problem after liver transplantation,” *Liver Transplantation*, vol. 12, no. 6, pp. 928–933, 2006.
 - [31] R. van den Berg-Emons, G. Kazemier, B. van Ginneken, C. Nieuwenhuijsen, H. Tilanus, and H. Stam, “Fatigue, level of everyday physical activity and quality of life after liver transplantation,” *Journal of Rehabilitation Medicine*, vol. 38, no. 2, pp. 124–129, 2006.
 - [32] B. T. J. van Ginneken, R. J. G. van den Berg-Emons, G. Kazemier, H. J. Metselaar, H. W. Tilanus, and H. J. Stam, “Physical fitness, fatigue, and quality of life after liver transplantation,” *European Journal of Applied Physiology*, vol. 100, no. 3, pp. 345–353, 2007.
 - [33] B. T. J. Van Ginneken, R. J. G. van den Berg-Emons, A. van der Windt et al., “Persistent fatigue in liver transplant recipients: a two-year follow-up study,” *Clinical Transplantation*, vol. 24, no. 1, pp. E10–E16, 2010.
 - [34] F. Åberg, A. M. Rissanen, H. Sintonen, R. P. Roine, K. Höckerstedt, and H. Isoniemi, “Health-related quality of life and employment status of liver transplant patients,” *Liver Transplantation*, vol. 15, no. 1, pp. 64–72, 2009.
 - [35] P. C. Adams, C. N. Ghent, D. R. Grant, and W. J. Wall, “Employment after liver transplantation,” *Hepatology*, vol. 21, no. 1, pp. 140–144, 1995.
 - [36] H. Bownik and S. Saab, “Health-related quality of life after liver transplantation for adult recipients,” *Liver Transplantation*, vol. 15, no. 2, pp. S42–S49, 2009.
 - [37] M. Aadahl, B. A. Hansen, P. Kirkegaard, and M. Groenvold, “Fatigue and physical function after orthotopic liver transplantation,” *Liver Transplantation*, vol. 8, no. 3, pp. 251–259, 2002.
 - [38] A. E. de Rijk, K. M. G. Schreurs, and J. M. Bensing, “What is behind ‘I’m so tired’? Fatigue experiences and their relations to the quality and quantity of external stimulation,” *Journal of Psychosomatic Research*, vol. 47, no. 6, pp. 509–523, 1999.
 - [39] T. Cowling, L. W. Jennings, R. M. Goldstein et al., “Liver transplantation and health-related quality of life: scoring differences between men and women,” *Liver Transplantation*, vol. 10, no. 1, pp. 88–96, 2004.
 - [40] C. M. Norris, W. A. Ghali, P. D. Galbraith, M. M. Graham, L. A. Jensen, and M. L. Knudtson, “Women with coronary artery disease report worse health-related quality of life outcomes compared to men,” *Health and Quality of Life Outcomes*, vol. 2, article 21, 2004.

- [41] E. West and S. Wållberg-Jonsson, "Health-related quality of life in Swedish men and women with early rheumatoid arthritis," *Gender Medicine*, vol. 6, no. 4, pp. 544–554, 2009.